Background Pembrolizumab monotherapy showed durable antitumour activity and manageable
safety in patients with metastatic triple-negative breast cancer. We aimed to examine …

Background Pembrolizumab showed durable antitumour activity and manageable safety in
metastatic triple-negative breast cancer in the single-arm KEYNOTE-012 and KEYNOTE-086 …

Background Breast cancer is characterised by genomic alterations. We did a multicentre
molecular screening study to identify abnormalities in individual patients with the aim of …

Brain metastases (BM) are the most common intracranial neoplasm in adults. Initially
considered as an essentially terminal stage of advanced cancer, BM are increasingly being …

Aim Real-life analysis of overall survival (OS) trends among metastatic breast cancer (MBC)
patients may help define medical needs and evaluate the impact of public health …

Cancer progression is driven in part by genomic alterations 1 . The genomic characterization
of cancers has shown interpatient heterogeneity regarding driver alterations 2 , leading to …

Purpose The activity and safety of eribulin mesylate (E7389), a nontaxane microtubule
dynamics inhibitor with a novel mechanism of action, were evaluated in patients with locally …

Background The poly(adenosine diphosphate–ribose) inhibitor talazoparib has shown antitumor
activity in patients with advanced breast cancer and germline mutations in BRCA1 and …

Paclitaxel is an antimicrotubule agent that induces mitotic block and apoptosis. We show for
the first time that paclitaxel acts directly on mitochondria isolated from human cancer cells. In …

Introduction Breast cancer is a complex and heterogeneous disease at the molecular level.
Evolution is difficult to predict according to classical histoclinical prognostic factors. Different …